References
1. He L, Hannon GJ (2010) MicroRNAs: small
RNAs with a big role in gene regulation. Nat
Rev Genet 5:522–531
2. Griffiths-Jones S (2004) The microRNA registry. Nucleic Acids Res 32:D109–D111
3. Monga I, Kumar M (2019) Computational
resources for prediction and analysis of functional miRNA and their targetome. Methods
Mol Biol 1912:215–250
4. Lim LP, Lau NC, Garrett-Engele P et al (2005)
Microarray analysis shows that some microRNAs downregulate large numbers of target
mRNAs. Nature 433:769–773
5. Filipowicz W, Jaskiewicz L, Kolb FA et al
(2005) Post-transcriptional gene silencing by
siRNAs and miRNAs. Curr Opin Struct Biol
15:331–341
6. Saliminejad K, Khorram Khorshid HR, Soleymani Fard S et al (2019) An overview of microRNAs: biology, functions, therapeutics, and
analysis
methods.
J
Cell
Physiol
234:5451–5465
7. Laina A, Gatsiou A, Georgiopoulos G et al
(2018) RNA therapeutics in cardiovascular
precision medicine. Front Physiol 9:953
8. Bardin P, Sonneville F, Corvol H et al (2018)
Emerging microRNA therapeutic approaches
for cystic fibrosis. Front Pharmacol 9:1113
9. Finotti A, Fabbri E, Lampronti I et al (2019)
MicroRNAs and long non-coding RNAs in
genetic diseases. Mol Diagn Ther 23:155–171
10. Lima JF, Cerqueira L, Figueiredo C et al
(2018) Anti-miRNA oligonucleotides: a comprehensive guide for design. RNA Biol
15:338–352
11. Kwok GT, Zhao JT, Weiss J et al (2017) Translational applications of microRNAs in cancer,
and therapeutic implications. Noncoding RNA
Res 2:143–150
12. Li Y, Wang Y, Shen X, Han X (2019) miR-128
functions as an oncomiR for the downregulation of HIC1 in breast cancer. Front Pharmacol
10:1202
13. Kim J, Siverly AN, Chen D et al (2016) Ablation of miR-10b suppresses oncogene-induced
mammary tumorigenesis and metastasis and
reactivates tumor-suppressive pathways. Cancer Res 76:6424–6435
14. Gambari R, Brognara E, Spandidos DA et al
(2016) Targeting oncomiRNAs and mimicking
Fig. 6 Effects of argininocalix[4]arene 1 on viability, cell proliferation, and morphology of U251 cells. (a)
Viability profile in U251 cells was reported for three incremental concentrations of argininocalix[4]arene 1:
1.25, 2.5, and 10 μM. The assay was conducted after 72-h transfection. (b–d) Lack of alteration of cell growth
and morphology of glioma U251 cells treated for 72 h with the indicated concentrations of argininocalix[4]
arene 1 (b). In panel (c) and (d), representative pictures are shown of control untreated U251 cells (c) and
U251 treated with 2.5 μM of argininocalix[4]arene 1 (d). Modified from Gasparello et al. [63]
140
Alessia Finotti et al.
1. He L, Hannon GJ (2010) MicroRNAs: small
RNAs with a big role in gene regulation. Nat
Rev Genet 5:522–531
2. Griffiths-Jones S (2004) The microRNA registry. Nucleic Acids Res 32:D109–D111
3. Monga I, Kumar M (2019) Computational
resources for prediction and analysis of functional miRNA and their targetome. Methods
Mol Biol 1912:215–250
4. Lim LP, Lau NC, Garrett-Engele P et al (2005)
Microarray analysis shows that some microRNAs downregulate large numbers of target
mRNAs. Nature 433:769–773
5. Filipowicz W, Jaskiewicz L, Kolb FA et al
(2005) Post-transcriptional gene silencing by
siRNAs and miRNAs. Curr Opin Struct Biol
15:331–341
6. Saliminejad K, Khorram Khorshid HR, Soleymani Fard S et al (2019) An overview of microRNAs: biology, functions, therapeutics, and
analysis
methods.
J
Cell
Physiol
234:5451–5465
7. Laina A, Gatsiou A, Georgiopoulos G et al
(2018) RNA therapeutics in cardiovascular
precision medicine. Front Physiol 9:953
8. Bardin P, Sonneville F, Corvol H et al (2018)
Emerging microRNA therapeutic approaches
for cystic fibrosis. Front Pharmacol 9:1113
9. Finotti A, Fabbri E, Lampronti I et al (2019)
MicroRNAs and long non-coding RNAs in
genetic diseases. Mol Diagn Ther 23:155–171
10. Lima JF, Cerqueira L, Figueiredo C et al
(2018) Anti-miRNA oligonucleotides: a comprehensive guide for design. RNA Biol
15:338–352
11. Kwok GT, Zhao JT, Weiss J et al (2017) Translational applications of microRNAs in cancer,
and therapeutic implications. Noncoding RNA
Res 2:143–150
12. Li Y, Wang Y, Shen X, Han X (2019) miR-128
functions as an oncomiR for the downregulation of HIC1 in breast cancer. Front Pharmacol
10:1202
13. Kim J, Siverly AN, Chen D et al (2016) Ablation of miR-10b suppresses oncogene-induced
mammary tumorigenesis and metastasis and
reactivates tumor-suppressive pathways. Cancer Res 76:6424–6435
14. Gambari R, Brognara E, Spandidos DA et al
(2016) Targeting oncomiRNAs and mimicking
Fig. 6 Effects of argininocalix[4]arene 1 on viability, cell proliferation, and morphology of U251 cells. (a)
Viability profile in U251 cells was reported for three incremental concentrations of argininocalix[4]arene 1:
1.25, 2.5, and 10 μM. The assay was conducted after 72-h transfection. (b–d) Lack of alteration of cell growth
and morphology of glioma U251 cells treated for 72 h with the indicated concentrations of argininocalix[4]
arene 1 (b). In panel (c) and (d), representative pictures are shown of control untreated U251 cells (c) and
U251 treated with 2.5 μM of argininocalix[4]arene 1 (d). Modified from Gasparello et al. [63]
140
Alessia Finotti et al.